Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review

• Published in: Journal of psychiatric research 2023-08, Vol.164, p.80-89
• Main Authors: Cooper, Daniel H., Ramachandra, Ranuk, Ceban, Felicia, Di Vincenzo, Joshua D., Rhee, Taeho Greg, Mansur, Rodrigo B., Teopiz, Kayla M., Gill, Hartej, Ho, Roger, Cao, Bing, Lui, Leanna M.W., Jawad, Muhammad Youshay, Arsenault, Juliet, Le, Gia Han, Ramachandra, Diluk, Guo, Ziji, McIntyre, Roger S.
• Format: Article
• Language: English
• Subjects: Depression; Depression - drug therapy; Depression - etiology; Diabetes mellitus; Diabetes Mellitus, Type 2 - chemically induced; Diabetes Mellitus, Type 2 - complications; GLP-1; GLP-1 receptor agonist; Glucagon-Like Peptide 1 - adverse effects; Glucagon-Like Peptide 1 - agonists; Glucagon-Like Peptide-1 Receptor - agonists; Humans; Hypoglycemic Agents - adverse effects; Incretin; Neuroprotective; Protective Factors; Retrospective Studies
• ISSN: 0022-3956; 1879-1379
• DOI: 10.1016/j.jpsychires.2023.05.041

Glucagon-like peptide 1 (GLP-1) receptor agonists are widely used for glycemic control in patients with diabetes mellitus (DM) and are primarily indicated for type 2 diabetes mellitus (T2DM). GLP-1 receptor agonists have also been shown to have neuroprotective and antidepressant properties. Replicated evidence suggests that individuals with DM are significantly more likely to develop depression. Herein, we aim to investigate whether GLP-1 receptor agonists can be used prophylactically on patients with DM to lower the risk of incident depression. We conducted a systematic search for English-language articles published on the PubMed/MEDLINE, Scopus, Embase, APA, PsycInfo, Ovid and Google Scholar databases from inception to June 6, 2022. Four retrospective observational studies were identified that evaluated the neuroprotective effects of GLP-1 receptor agonists on incident depression in patients with DM. We found mixed results with regards to lowering the risk of incident depression, with two studies demonstrating a significant reduction in risk and two studies showing no such effect. A single study found that dulaglutide may lower susceptibility to depression. Our results were limited by high interstudy heterogeneity, paucity of literature, and lack of controlled trials. While we did not find evidence of GLP-1 receptor agonists significantly lowering risk of incident depression in patients with DM, promising neuroprotective data presented in two of the included papers, specifically on dulaglutide where information is scarce, provide the impetus for further investigation. Future research should focus on better elucidating the neuroprotective potential of different classes and doses of GLP-1 receptor agonists using controlled trials.